DaraPay Announces Strategic Partnership with Chinese Tech Giant- Alipay
DaraPay, the leading mobile E-wallet and payment service providers, today announces its partnership with Alipay, world’s leading payment and lifestyle platform operated by Ant Financial. With this partnership, Chinese tourists can scan and pay with their Alipay app at all DaraPay merchants with more than 3,000 outlets in Phnom Penh, Kandal, Kampong Cham, Siem Reap and Battambang province.
Alipay serves over 1.2 billion users together with its regional partners and is the preferred payment method of Chinese tourists1.
Through this strategic partnership, the two partners are looking to integrate their respective systems with one another and offer the market a flexible, on-demand digital payment solution through which Chinese tourists can conveniently use during their visit to Cambodia.
With the system now in place, Alipay users are no longer required to withdraw cash or perform cross-app money transfer to make payments across the Kingdom. They can simply complete their purchases by scanning the special QR code available at DaraPay-enabled merchant partners.
“We are excited to work with Alipay,” said Mr. Phok Ratha, General Manager of DaraPay. “Through this collaboration, Alipay users can now benefit from the convenience, simplicity, and security of our integrated system and merchant partners while enjoying their vacation in Cambodia.”
With DaraPay's more than 3,000 merchant partners, finding a store or service that accepts this integrated mobile payment should not be a trouble. Whether it is a transaction at a restaurant, café, and supermarket or payment for services such as ride-hailing, hotel, and entertainments, Chinese tourists can truly benefit by choosing the services of DaraPay’s merchant partners. Alipay customers who love shopping for apparel or trying out all types of delicious food can enjoy with the most popular Chinese tourist malls: Sorya Center Point or The Olympia Mall located at the heart of Phnom Penh City.
The future bodes well for the two partners with the number of Chinese tourists visiting the Kingdom continues to grow. Last year, statistically the nation welcomed over 1.7 million Chinese tourists, and the number is expected to rise to 3 million by 2020 and 5 million by 2025.
As the number of Chinese tourists to the Kingdom continues to surge, and following its strategic road map, DaraPay is on track with its collaboration with leading fintech platform Alipay.
Mr. Ratha continued, "The partnership with Alipay is an important step that takes DaraPay to the next level of our business development. We do not only collaborate with local businesses but we are also actively working with international partners as part of our new strategic roadmap to enter a new horizon. In the future, we are looking to collaborate with other international partners to bring better and more innovative services to cater to our customers both the locals and international ones.”
About DaraPay:
DaraPay is a trademark of CANADIA-FULLERTON MOBILE MONEY PLC., a corporation duly established in 2016. DaraPay is a joint venture between Canadia Investment Holding (CIH) of Cambodia and Fullerton Financial Capital (FFC), a subsidiary of Fullerton Financial Holdings (FHH) of Singapore, for the purpose of operating a mobile wallet and payments business in Cambodia. DaraPay’s services include Local Money Remittance, Cash-In / Cash Out, Utilities Bill Payments, Phone Top Up, Bill Payment, E-commerce Payment, Merchant Payment, Loan Repayment, Loan Referral, Payroll service, Mobile Wallet and other financial related products. As of August 2019, DaraPay has more than 4,500 agents nationwide and has more than 3,000 merchants available to accept the payment. Through DaraPay, thousands of people and families in both provinces and urban cities are sending money anywhere, any time at the peace of mind.
Don’t have DaraPay App yet?
Android & iOS users, download now:
https://goo.gl/7tvY1E
DaraPay: Fast, Secure and Everywhere.
About Alipay:
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191117005080/en/
Contact information
For media inquiry:
Mr. Phok Ratha, General Manager, CANADIA-FULLERTON MOBILE MONEY PLC.
Tel: +855 81 799 888
Email: ratha.phok@darapay.com.kh
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom